Benitec Biopharma Inc

NASDAQ:BNTCUnited States

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Contact Information

Headquarters

3940 Trust WayHAYWARD, CA, United States 94545

Phone

510-780-0819

Fax

302-636-5454

Executives

Executive Chairman of the Board, Chief Executive Officer

Jerel Banks

Executive Director

Megan Boston

Independent Director

J. Kevin Buchi

Independent Director

Peter Francis

Independent Director

Kishan Mehta